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SUMMARY
Since its discovery in 1972, cyclosporin A (CyA) has been widely used in the experimental
treatment of multiple inflammatory diseases considered to be of immime-mediated aetiology.
In dermatology, oral CyA is most effective in the treatment of psoriasis and has been used
successfully for plaque-type, pustular and erythrodermic forms of the disease. While dosages
ranging from i to 14 mg/kg/day have been used, a starting dose of 4 mg/kg/day gives a rapid
response with few side-effects. Nephrotoxicity remains the greatest concern in long-term use
of the drug. Although intralesional CyA has proven effective in psoriasis, topical preparations
have not. It is hoped that future research will provide effective topical formulations of CyA
which are efficacious without the risks inherent in systemic administration.
Cyclosporin A (CyA) is a cyclic polypeptide of fungal origin that was discovered in 1972. Due
to its marked immunosuppressive effects and lack of myelotoxicity, the drug rapidly became
the mainstay of therapy for organ transplantation. In recent years, the drug has been used in
the experimental treatment of rheumatoid and psoriatic arthritis, insulin-dependent diabetes
mellitus, inflammatory bowel diseases, myasthenia gravis. Grave's disease and uveitis.'
Cyclosporin A has been used as the sole therapy for psoriasis,̂ "* alopecia areata,'''° Beh^et's
disease,"'" atopic dermatitis,'^'"* pyoderma gangrenosum'^'" and lichen planus.'*'̂ ° In com-
bination therapy with other immunosuppressive drugs, CyA has been shown to have a benefi-
cial effect in the treatment of dermatomyositis/polymyositis,^''^' systemic lupus erythema-
tosus,̂ "" '̂ pemphigus and pemphigoid.̂ '̂̂ *
In dermatology, the most dramatic effect of treatment with CyA is seen in psoriasis. Mueller
and Herrmann^' made the fortuitous discovery in 1979 that plaque-type psoriasis cleared in all
four patients who received the drug for psoriatic arthritis. Van Hooff et al. '° reported a renal
transplant recipient whose psoriasis cleared after initiation of CyA treatment.
The first controlled study to evaluate the efficacy of CyA in psoriasis was done by us in 1986.'
Twenty-one patients were enrolled in a double-blind cross-over study. All patients had severe
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plaque-type psoriasis which had been recalcitrant to treatment with topical corticosteroids,
anthralin (dithranol) and tar as well as to ultraviolet B (UVB), oral psoralen and ultraviolet A
(PUVA), or methotrexate. Patients received either placebo or CyA at a dose of 14 mg/kg/day.
Within 4 weeks of therapy, 20 of 21 patients given the drug showed significant to complete
clearing of psoriasis. The patients who received placebo showed no response prior to cross-over
to active drug treatment.
In an open study, Wentzell et al.^^ noted marked improvement to complete clearance in 14
patients given CyA at 5-15 mg/kg/day for i month. These excellent responses were seen in
patients regardless of whether they had pustular, erythrodermic or plaque-type psoriasis.
Multiple studies conducted both in Europe and in the U.S. have now shown that low-dose
CyA can induce clearing of psoriasis. Marks'^ treated nine patients who had plaque-type
psoriasis with a starting dose of i mg/kg/day of CyA, increasing the dose every 2 weeks as
necessary, vintil improvement was noted or up to a maximum dose of 5 mg/kg/day. Within 20
weeks, all nine patients showed improvement, and clearance was achieved in seven. The
average dose required for a clinical response was 33 mg/kg/day.
Griffiths et al.^ treated 10 patients with CyA at 2-4 mg/kg/day for 3 months and concluded
that the lowest effective dose of the drug was 3 mg/kg/day. Fry et al.^^ found that they were
able to maintain near-complete remission of psoriasis in eight patients, who were followed for
up to 66 weeks, using CyA dosages of 1-4 mg/kg/day. Meinardi and Bos'** induced remissions
of psoriasis in 12 patients with a mean dose of 6 mg/kg/day. On reducing the dose of the drug,
each patient had a dose level of CyA below which a flare of psoriasis was inevitable. This dose
threshold ranged from 1-6-7 mg/kg/day which, for a given patient, varied with time. Picascia
et al.^^ used a starting dose of CyA of 7-5 mg/kg/day to treat three patients whose plaque-type
psoriasis had failed to respond to other systemic therapies. Two of these patients cleared
completely within 3 weeks and one was cleared by 8 weeks. One patient has been maintained
on 35 mg/kg/day while the other two have been successfully switched to PUVA therapy or
etretinate and UVB while maintaining good control of their disease.
We conducted a dose-finding double-blind placebo-controlled trial using CyA in the treat-
ment of severe recalcitrant psoriasis.'* Eighty-five patients were enrolled in the first phase of
this study, during which patients received either placebo, 3 mg, 5 mg or 75 mg/kg/day of the
drug. Within i month of therapy, the percent improvement from baseline in each group was
0%, 42%, 61% and 79%, respectively, for each dose group. By Week 8 of therapy, the
percentage improvement was - 5 % , 54%, 82% and 93%, respectively. In order to achieve a
greater than 90% clearance by Week 16, 60% of patients taking 3 mg/kg/day required an
increase in dosage compared with 25% of those in the 5 mg/kg/day dosage group and 13% of
those receiving 75 mg/kg/day. Dosage reduction for side-effects or signs of toxicity was
necessary in 0%, 0%, 5% and 33% of each group respectively. In general, the drug was very
well tolerated and side-effects were similar to those reported in others taking CyA.
We suggest that CyA at 4 mg/kg/day may be the best starting dose as this can be expected
to produce a significant improvement within 1-2 months of therapy with minimal risk of
short-term toxicity. If an increase in dosage is required, most patients can be expected to
tolerate 5 mg/kg/day, at least for several weeks to months.
Cyclosporin A has also been shown to be effective in non-plaque-type psoriasis. Picascia et
al.^ treated two patients who had erythrodermic psoriasis with CyA at approximately 8
mg/kg/day; complete clearance was noted in both patients within 3 weeks. After clearance was
achieved, one patient was maintained on CyA 2 mg/kg/day and had plaque-type psoriasis on
less than 20% of her body. The second patient was controlled with PUVA therapy and CyA
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at 1-7 mg/kg/day.'' Meinardi et al.^'' reported successfully treating a patient with generalized
von Zumbusch pustular psoriasis using CyA at 5-12 mg/kg/day. We treated one patient, who
had a 30-year intermittent history of pustular psoriasis, with CyA at a starting dose of 7-5
mg/kg/day.'* Due to his excellent clinical response, we were able to gradually taper his dose
to 1-5 mg/kg/day over 5 months. A mild flare of disease at this dose required a gradual dosage
increase of 3-5 mg/kg/day, which again resulted in a remission.
A recalcitrant case of acrodermatitis continua cleared for the first time in 10 years after
therapy was initiated with CyA at 14 mg/kg/day, followed by gradual tapering to a dose of 5
mg/kg/day.'' Six patients with palmoplantar pustulosis showed a dramatic improvement with
CyA at 25 mg/kg/day.''° We treated two patients who had acrodermatitis continua with CyA
at 6 mg/kg/day."' One patient cleared completely and the other showed no new pustulation
within 8 weeks of initiating therapy.
Intralesional CyA can be effective in the treatment of plaque-type psoriasis. Ho et al.^^
conducted a double-blind trial of six patients with plaque-type psoriasis which compared
intralesional injections of CyA (17 mg/ml), vehicle and saline which were given three times per
week. Within 4 weeks, significant improvement to complete clearing was seen in all CyA-treat-
ed plaques in contrast to vehicle- or saline-treated plaques, which showed minimal to no
improvement. Both the solution of CyA and its vehicle caused pain on injection in all the
patients, apparently as the result of the vehicle rather than the drug itself. In contrast, CyA
administered once weekly was no better than its vehicle in improving the plaques of psoriasis.
Systemic absorption of the drug was negligible, suggesting that CyA need not be given
systemically to be effective in the treatment of psoriasis. Similar results were also found in a
study of 10 patients.*"
In contrast, topical CyA has, so far, been ineffective in the treatment of psoriasis. In a
placebo-controlled study, Griffiths et al.** treated six patients twice daily for 4 weeks with a 2%
CyA ointment. No difference was noted in efficacy between the drug and placebo. In an open
trial, we treated 10 patients with a 10% CyA solution, which was also found to be ineffective,''̂
and a similar lack of response was noted in six patients treated with a 5% topical CyA
solution."** Bousema et al.*'' found 10% topical CyA gel to be ineffective.
Schulze et al.*^ treated six patients in a placebo-controlled trial using a 5% CyA ointment,
under plastic-fllm occlusion, for 2-3 weeks. Immunostaining revealed a marked decrease in the
mmiber of infiltrating neutrophils in the epidermis and papillary dermis, but no change in the
helper/suppressor T-cell ratio. Despite drug levels in CyA-treated plaques comparable to
those observed in patients given oral CyA, no change in epidermal cell kinetics was noted after
topical application of the drug, and no clinical improvement was seen. This is in contrast to
our study of intralesional CyA in which a clinical response was preceded, in many cases, by a
signiflcant reduction in the number of antigen-presenting cells, epidermal and dermal mono-
cytes, and keratinocyte intercellular adhesion molecule-1 expression."*^
It is not known why topical CyA formulations have been ineffective in the treatment of
psoriasis. The clearing in response to intralesional CyA demonstrates that systemic administra-
tion should not be required for efficacy. The failure of psoriasis to improve in response to
topical applications of the drug may be due to an inadequate concentration of the drug reaching
the necessary site(s), poor percutaneous absorption,"" rapid redistribution of the drug, drug
inactivation or by non-specific binding to proteins in the skin.
The discovery of CyA in 1972 and the subsequent demonstration of its marked efficacy in
psoriasis have ushered in a new era of both research and therapy for this chronic disease. The
dramatic effects of CyA in many dermatological diseases has not only provided new therapeutic
24 M.S.Fradin et al.
options, but has also expanded our understanding of the pathophysiology of many diseases and
opened up new avenues of research. It is hoped that, in the future, effective CyA topical
formulations or oral analogues with less toxicity will be discovered.
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